These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 32296125)

  • 1. Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting.
    Viola D; Dona A; Caserta E; Troadec E; Besi F; McDonald T; Ghoda L; Gunes EG; Sanchez JF; Khalife J; Martella M; Karanes C; Htut M; Wang X; Rosenzweig M; Chowdhury A; Sborov D; Miles RR; Yazaki PJ; Ebner T; Hofmeister CC; Forman SJ; Rosen ST; Marcucci G; Shively J; Keats JJ; Krishnan A; Pichiorri F
    Leukemia; 2021 Jan; 35(1):189-200. PubMed ID: 32296125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity.
    Naeimi Kararoudi M; Nagai Y; Elmas E; de Souza Fernandes Pereira M; Ali SA; Imus PH; Wethington D; Borrello IM; Lee DA; Ghiaur G
    Blood; 2020 Nov; 136(21):2416-2427. PubMed ID: 32603414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CD38
    Sarkar S; Chauhan SKS; Daly J; Natoni A; Fairfield H; Henderson R; Nolan E; Swan D; Hu J; Reagan MR; O'Dwyer M
    Cancer Immunol Immunother; 2020 Mar; 69(3):421-434. PubMed ID: 31919623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells.
    Clara JA; Levy ER; Reger R; Barisic S; Chen L; Cherkasova E; Chakraborty M; Allan DSJ; Childs R
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35135865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daratumumab prevents programmed death ligand-1 expression on antigen-presenting cells in de novo multiple myeloma.
    Stocker N; Gaugler B; Ricard L; de Vassoigne F; Marjanovic Z; Mohty M; Malard F
    Cancer Med; 2020 Mar; 9(6):2077-2084. PubMed ID: 31991058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma.
    Cho N; Ko S; Shokeen M
    Mol Imaging Biol; 2021 Apr; 23(2):186-195. PubMed ID: 32964391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.
    Paulus A; Manna A; Akhtar S; Paulus SM; Sharma M; Coignet MV; Jiang L; Roy V; Witzig TE; Ansell SM; Allan J; Furman R; Aulakh S; Manochakian R; Ailawadhi S; Chanan-Khan AA; Sher T
    Br J Haematol; 2018 Oct; 183(2):196-211. PubMed ID: 30080238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
    Adams HC; Stevenaert F; Krejcik J; Van der Borght K; Smets T; Bald J; Abraham Y; Ceulemans H; Chiu C; Vanhoof G; Usmani SZ; Plesner T; Lonial S; Nijhof I; Lokhorst HM; Mutis T; van de Donk NWCJ; Sasser AK; Casneuf T
    Cytometry A; 2019 Mar; 95(3):279-289. PubMed ID: 30536810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma.
    Panaampon J; Kariya R; Okada S
    Cancer Immunol Immunother; 2022 May; 71(5):1017-1031. PubMed ID: 34545416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
    Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
    Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
    [No Abstract]   [Full Text] [Related]  

  • 11. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.
    Overdijk MB; Verploegen S; Bögels M; van Egmond M; Lammerts van Bueren JJ; Mutis T; Groen RW; Breij E; Martens AC; Bleeker WK; Parren PW
    MAbs; 2015; 7(2):311-21. PubMed ID: 25760767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
    Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
    Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Bortezomib Regimens and Daratumumab Monotherapy on Cellular Immunity in Multiple Myeloma Patients.
    Kakoo A; Rasheed T; Al-Attar M
    Iran J Immunol; 2021 Jun; 18(2):119-129. PubMed ID: 34190693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma.
    Cho H; Kim KH; Lee H; Kim CG; Chung H; Choi YS; Park SH; Cheong JW; Min YH; Shin EC; Kim JS
    Clin Cancer Res; 2021 May; 27(10):2947-2958. PubMed ID: 33602683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma.
    Saltarella I; Desantis V; Melaccio A; Solimando AG; Lamanuzzi A; Ria R; Storlazzi CT; Mariggiò MA; Vacca A; Frassanito MA
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias.
    Zambello R; Barilà G; Manni S; Piazza F; Semenzato G
    Cells; 2020 Mar; 9(3):. PubMed ID: 32245149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.
    Zhu C; Song Z; Wang A; Srinivasan S; Yang G; Greco R; Theilhaber J; Shehu E; Wu L; Yang ZY; Passe-Coutrin W; Fournier A; Tai YT; Anderson KC; Wiederschain D; Bahjat K; Adrián FJ; Chiron M
    Front Immunol; 2020; 11():1771. PubMed ID: 32922390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease.
    Shrestha P; Astter Y; Davis DA; Zhou T; Yuan CM; Ramaswami R; Wang HW; Lurain K; Yarchoan R
    Oncoimmunology; 2023; 12(1):2163784. PubMed ID: 36632565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.
    Hu Y; Liu H; Fang C; Li C; Xhyliu F; Dysert H; Bodo J; Habermehl G; Russell BE; Li W; Chappell M; Jiang X; Ondrejka SL; Hsi ED; Maciejewski JP; Yi Q; Anderson KC; Munshi NC; Ao G; Valent JN; Lin J; Zhao J
    Cancer Res; 2020 May; 80(10):2031-2044. PubMed ID: 32193289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications.
    Ogiya D; Liu J; Ohguchi H; Kurata K; Samur MK; Tai YT; Adamia S; Ando K; Hideshima T; Anderson KC
    Blood; 2020 Nov; 136(20):2334-2345. PubMed ID: 32844992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.